raloxifene hydrochloride has been researched along with Hormone-Dependent Neoplasms in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 19 (65.52) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Powles, TJ | 2 |
| Howell, A | 1 |
| Cutuli, B; Kerbrat, P; Lesur, A; Namer, M | 1 |
| Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Brown, PH; Hortobagyi, GN | 1 |
| Ravdin, PM | 1 |
| Cuzick, J | 1 |
| Hong, YJ; Kim, BC; Kim, HT; Kim, IY; Kim, SJ; Lee, DK; Morton, RA; Seo, JM; Seong, DH | 1 |
| Amant, F; Joubert, A; Lindeque, BG; Lottering, ML; Thaver, V; Vergote, I | 1 |
| Hayes, DF | 1 |
| Lo, SS; Vogel, VG | 1 |
| Dunn, BK; Ford, LG; Wickerham, DL | 1 |
| Jordan, VC | 2 |
| McNeil, C | 1 |
| Gradishar, WJ; Jordan, VC; Morrow, M; Pierce, LJ; Takei, H | 1 |
| Manni, A | 1 |
| Boersma, CJ; Dijkema, R; Mosselman, S; Mulder, WR; Olijve, W; van den Wijngaard, A; van Zoelen, EJ | 1 |
| O'Regan, RM | 1 |
| Jordan, VC; O'Regan, RM | 1 |
| Gradishar, WJ; O'Regan, RM | 1 |
| Fentiman, IS; Salih, AK | 1 |
| Bentrem, DJ; Craig Jordan, V | 1 |
| Blau, R; Lower, EE; Rohatgi, N | 1 |
| Anthony, M; Arun, B; Dunn, B | 1 |
| Kim, BC; Kim, IY; Kim, SJ; Leach, F; Lee, DK; Morton, RA; Remaley, AT; Seong, DH | 1 |
| Bennett, JA; Bowser, SS; Bradley, L; Dickerman, HW; Gierthy, JF; Lincoln, DW; Roth, KE | 1 |
| Gottardis, MM; Jordan, VC | 1 |
14 review(s) available for raloxifene hydrochloride and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Prevention of breast cancer using SERMs.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
The endocrine prevention of breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
[Breast cancer chemoprevention. Rational, trials results and future].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Family Health; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).
Topics: Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Prevention of hormone-related cancers: breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
SERMs: meeting the promise of multifunctional medicines.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Evidence-Based Medicine; Female; Humans; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; United States | 2007 |
Status of antiestrogen breast cancer prevention trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Female; Genes, BRCA1; Humans; Italy; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene; United Kingdom; United States | 1998 |
Current controversies in breast cancer management.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Patient Selection; Piperidines; Radiotherapy, Adjuvant; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Tamoxifen | 1999 |
Hormonal approaches to the chemoprevention of endocrine-dependent tumors.
Topics: Aromatase Inhibitors; Chemoprevention; Endocrine Gland Neoplasms; Enzyme Inhibitors; Estrogen Receptor Modulators; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Tamoxifen | 1999 |
Chemoprevention of breast cancer.
Topics: Adult; Aged; Animals; Anticarcinogenic Agents; Bone and Bones; Breast Diseases; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Endometrial Neoplasms; Estrogens; Female; Gonadal Steroid Hormones; Humans; Lipids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis, Postmenopausal; Pilot Projects; Precancerous Conditions; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproductive History; Risk Factors; Safety; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Tamoxifen to raloxifene and beyond.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Breast cancer prevention: present and future.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2001 |
Tamoxifen, raloxifene and the prevention of breast cancer.
Topics: Adult; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Coronary Disease; Drug Design; Endometrial Neoplasms; Estrogens; Female; Humans; Incidence; Mammary Neoplasms, Experimental; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2002 |
The search for the ideal SERM.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Cognition; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
1 trial(s) available for raloxifene hydrochloride and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cataract; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Uterus | 2010 |
14 other study(ies) available for raloxifene hydrochloride and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Two good choices to prevent breast cancer: great taste, less filling.
Topics: Adenocarcinoma; Breast Neoplasms; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Humans; Incidence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2010 |
The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention.
Topics: Adenocarcinoma; Breast Neoplasms; Decision Support Techniques; Drug Utilization; Estrogens; Female; Humans; Incidence; Internet; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Patient Education as Topic; Physicians, Family; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Long-term follow-up in cancer prevention trials (It ain't over 'til it's over).
Topics: Adenocarcinoma; Breast Neoplasms; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Incidence; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Papillomavirus Vaccines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Sample Size; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Cervical Neoplasms | 2010 |
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Topics: Apoptosis; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured | 2002 |
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth.
Topics: Antineoplastic Agents, Hormonal; Carcinosarcoma; Cell Cycle; Cell Division; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Progesterone; Raloxifene Hydrochloride; Tamoxifen; Triptorelin Pamoate; Uterine Neoplasms | 2003 |
Playing the old piano: another tune for endocrine therapy?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Clinical Trials as Topic; Diethylstilbestrol; Disease Progression; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Male; Neoplasms, Hormone-Dependent; Ovariectomy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Treatment Outcome | 2003 |
In search of the perfect SERM: beyond tamoxifen and raloxifene.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 1998 |
Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells.
Topics: Adenocarcinoma; Base Sequence; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Breast Neoplasms; Cells, Cultured; Dimerization; Drug Design; Endometrial Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression Regulation; Humans; Molecular Sequence Data; Neoplasms, Hormone-Dependent; Organ Specificity; Osteoblasts; Osteogenesis; Osteoporosis; Osteosarcoma; Postmenopause; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Stimulation, Chemical; Transfection; Tumor Cells, Cultured | 2000 |
Selective estrogen-receptor modulators in 2001.
Topics: Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Pilot Projects; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis | 2001 |
Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
Topics: Amino Acid Substitution; Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen; Tumor Cells, Cultured | 2001 |
Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Estrogen Antagonists; Female; Hot Flashes; Humans; Libido; Middle Aged; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Time Factors; Vaginal Discharge; Weight Gain | 2002 |
Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Topics: Androgens; Apoptosis; Dose-Response Relationship, Drug; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptors, Androgen; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured | 2002 |
Estrogen-stimulation of postconfluent cell accumulation and foci formation of human MCF-7 breast cancer cells.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cattle; Cell Division; Contact Inhibition; Culture Media; Estradiol; Estrogens; Humans; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1991 |
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Topics: Animals; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Methylnitrosourea; Neoplasms, Hormone-Dependent; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen; Tamoxifen; Time Factors; Uterus | 1987 |